| Expression pattern: |
DN |
| Associated gene: |
- |
| Associated microRNA: |
- |
| Biological function: |
Promotes gemcitabine sensitivity (re-sensitizes gemcitabine-resistant bladder cancer cells), inhibits cell viability, and promotes apoptosis under gemcitabine treatment. |
| Molecular mechanism: |
Not established in this study; authors hypothesize a ceRNA (miRNA sponge) mechanism may be involved. |
| Biological pathway or process: |
chemoresistance (inhibits); apoptosis (promotes); proliferation (inhibits) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; Clinical Sample Validation; Survival Analysis; Transfection; CCK8; Annexin V/PI Flow Cytometry |
| Clinical significance: |
Low circHIPK3 expression is associated with higher pathological grade, lymph node metastasis, and gemcitabine chemotherapy insensitivity; circHIPK3 is an independent prognostic biomarker for BC patients. |
| Description: |
CircHIPK3 is down-regulated in bladder cancer tissues and cell lines and its low expression is associated with gemcitabine insensitivity. Overexpression of circHIPK3 re-sensitizes gemcitabine-resistant BC cells by lowering gemcitabine IC50, reducing viability, and increasing apoptosis, while the mechanism is not experimentally established in this work. |
| Confidence score: |
0.7036 |